Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.
*From the Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; and
†Weill Cornell Medicine, New York, NY.
Conflicts of Interest and Source of Funding: The Lymphoma Foundation, Rob and Karen Schneider and The Louis Schneider and Harry Davis Memorial Trust, The Adam R. Spector Foundation, The David R. and Patricia D. Atkinson Foundation, and Mr. and Mrs. Ernest Dicker.
Reprints: David J. Straus, MD, Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave Box 330 New York, NY 10065. E-mail: firstname.lastname@example.org.